Johnson & Johnson released its fourth-quarter and full-year 2025 financial results, underscoring broad-based growth, advancing innovation and a strengthening commercial portfolio. Chairman and Chief Executive Officer Joaquin Duato described 2025 as “a catapult year” for the company, driven by its largest portfolio…
Sanofi reported robust fourth-quarter and full-year 2025 results that reflect continued execution on its strategic priorities, strong commercial performance, disciplined cost management, and advancing R&D. Under the leadership of Chief Executive Officer Paul Hudson, the company delivered double-digit growth in ne…
Abbott reported solid fourth-quarter and full-year 2025 results, underscoring continued momentum across its diversified healthcare portfolio and positioning the company for faster growth in 2026, according to Chairman and CEO Robert B. Ford. For the fourth quarter ended December 31, 2025, Abbott posted reported sales…
Avantor Reports Q3 2025 Financial Results; CEO Emmanuel Ligner Highlights Strategic Actions for Long-Term Value Creation Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced its financial results for the thir…
Samsung Biologics, a leading global contract development and manufacturing organization (CDMO), has announced impressive third-quarter 2025 financial results, underscoring its position as a global powerhouse in biomanufacturing and biopharma services. For the quarter ended September 30, 2025, Samsung Biologics report…
Agilent CEO Padraig McDonnell announces Q3 2025 revenue of $1.74 billion, marking fifth straight quarter of core growth under Ignite Transformation. The company reported revenue of $1.74 billion, exceeding its guidance range and reflecting 10.1% reported growth and 6.1% core growth compared with the third quarter of …
Sandoz the global leader in generic and biosimilar medicines, announced its financial results for the first half of 2025, showcasing strong growth across its biosimilars portfolio, improved profitability, and continued strategic progress in global manufacturing and R&D expansion. At constant currencies (CC), net …
LEO Pharma delivered robust financial performance in H1 2025, marked by strong organic growth, improved profitability, and strategic milestones that strengthen its dermatology leadership. Under CEO Christophe Bourdon’s leadership, the company has enhanced its portfolio, improved margins, and positioned itself for sust…
Roche delivered a solid performance in the first half of 2025, showcasing strong revenue growth, higher profitability, key regulatory approvals, and significant pipeline advancements. Under the leadership of CEO Thomas Schinecker, Roche strengthened its pharmaceuticals portfolio, expanded its innovation pipeline, and …
Under Robert A. Michael’s leadership, AbbVie strengthened its innovation pipeline with multiple regulatory approvals and strategic R&D advancements, including Rinvoq’s new GCA indication and FDA’s accelerated approval for Emrelis. Combined with robust sales from immunology and neuroscience portfolios, AbbVie conti…
Page 3 of 3